ORIFARM

What ORIFARM does

ORIFARM is a private pharmaceutical company headquartered in Odense, Denmark, that manufactures and distributes generic medicines and healthcare products across European markets and the United States. The group operates in at least 16 countries, including Austria, Belgium, the Czech Republic, Denmark, Estonia, Finland, Germany, Latvia, Lithuania, the Netherlands, Norway, Poland, Spain, Sweden, the United Kingdom, and the United States, with dedicated country-level operations and reimbursement/market entry infrastructure evident from the corporate website.

The legal entity Orifarm Manufacturing Viminco A/S, operating under the trade name Viminco, historically served as a contract-based pharmaceutical manufacturer within the Orifarm Group. The parent entity, Orifarm Group A/S, sits at Energivej 15, 5260 Odense S, Denmark. According to the company's own website, Viminco A/S' manufacturing activities have been transferred to other Orifarm production sites, effectively consolidating the group's manufacturing footprint and winding down the standalone Viminco manufacturing brand.

The source material provides no detail on the group's pricing model, contract structure, specific product SKUs, customer mix, revenue split, or competitive positioning against other European generic manufacturers. No external investors, M&A activity, funding rounds, certifications, or named partnerships are disclosed. With 101-250 employees and a multi-country distribution footprint, ORIFARM appears to be a mid-sized European generics operator whose current strategic posture, based on the documented Viminco consolidation, is focused on internal efficiency rather than expansion.

Name

ORIFARM

Legal name

Orifarm Manufacturing Viminco A/S

Website

https://viminco.dk

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

ORIFARM is a private Danish pharmaceutical company headquartered in Odense that manufactures and distributes generic medicines and healthcare products across 16 European countries and the United States. The group's former contract-manufacturing subsidiary, Viminco A/S, has been consolidated into other Orifarm production sites.

Ownership category

akta.pro rank

Headquarters

HQ city

Skælskør

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Core offering

Orifarm Manufacturing Viminco A/S is a contract-based pharmaceuticals manufacturer producing generic medicines and healthcare products under the Orifarm Group umbrella. The company manufactures and distributes generic pharmaceutical products across European markets, with manufacturing operations historically consolidated into other Orifarm production sites.

Product overview

Orifarm is a pharmaceutical company offering generic medicines and healthcare products. The company operates across multiple European countries (Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, Germany, Latvia, Lithuania, Netherlands, Norway, Poland, Spain, Sweden, United Kingdom, United States). Viminco A/S manufacturing operations have been consolidated into other Orifarm production facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Orifarm Manufacturing — Viminco A/S (contract-based pharmaceuticals manufacturing) Contract manufacturing of generic pharmaceuticals and healthcare products for distribution across European markets, operated under the Orifarm Group umbrella. target buyer is pharmaceutical companies seeking contract manufacturing capacity, based on the explicit 'contract-based pharmaceuticals manufacturer' description.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Broad incumbents

• Helm AG: Hamburg-based distribution and CDMO group active in APIs, finished generics, and crop protection across global markets. Comparable to Viminco as a German/European pharma manufacturing and distribution counterpart.
• KRKA: Slovenian generics manufacturer with vertically integrated API and finished dose production sold across more than 50 countries. Comparable as a European-centric generic drug product manufacturer with similar regulatory breadth.
• Sandoz: Novartis' generics and biosimilars division, one of the largest European generics players with pan-European distribution. Comparable as a broad incumbent that competes and partners across the same European generics value chain as Orifarm/Viminco.
• STADA Arzneimittel: Major European generics and specialty pharma company headquartered in Germany, with extensive manufacturing and distribution across the same 16+ European countries where Viminco operates. Comparable as a broader incumbent in the generics value chain Viminco serves.
• Polpharma: Poland's largest generics manufacturer, producing APIs and finished dosage forms for European and emerging markets. Comparable to Viminco in scale, European geographic focus, and generic-pharma manufacturing model.

Direct peers

• Aenova Group: German CDMO with broad solid, semi-solid, and sterile manufacturing capabilities across multiple European sites. Closely comparable to Viminco in serving pharma innovators and generics companies with contract-based drug product manufacturing.
• Fareva: French pharmaceutical CDMO operating numerous European manufacturing sites for finished dosage forms, biologics fill-finish, and APIs. Comparable to Viminco as a multi-site European contract manufacturer with broad generic and branded pharma client base.
• Recipharm: Swedish-headquartered CDMO with multiple European manufacturing sites offering contract development and manufacturing of oral solids, injectables, and other dosage forms. Directly comparable to Viminco as a European contract pharma manufacturer serving multiple geographies.

Emerging players

• Catalent: Global CDMO with strong European operations in softgel, oral solids, biologics fill-finish, and clinical supply. Comparable to Viminco as a contract manufacturer offering integrated drug product services to pharma customers in Europe and beyond.
• Alcami: US-headquartered CDMO offering sterile fill-finish, oral solid dose, and lab services with European presence via acquired sites. Comparable to Viminco in offering contract manufacturing across multiple dosage forms to pharma and generics clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/viminco

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ORIFARM